Pharmacological Reviews, Vol 38, 1-20, Copyright © 1986 by American Society for Pharmacology and Experimental Therapeutics

Health aspects of cannabis

LE Hollister

Marijuana seems firmly established as another social drug in Western countries, regardless of its current legal status. Patterns of use vary widely. As with other social drugs, the pattern of use is critical in determining adverse effects on health. Perhaps the major area of concern about marijuana use is among the very young. Using any drug on a regular basis that alters reality may be detrimental to the psychosocial maturation of young persons. Chronic use of marijuana may stunt the emotional growth of youngsters. Evidence for an amotivational syndrome is largely based on clinical reports; whether marijuana use is a cause or effect is uncertain. A marijuana psychosis, long rumored, has been difficult to prove. No one doubts that marijuana use may aggravate existing psychoses or other severe emotional disorders. Brain damage has not been proved. Physical dependence is rarely encountered in the usual patterns of social use, despite some degree of tolerance that may develop. The endocrine effects of the drug might be expected to delay puberty in prepubertal boys, but actual instances have been rare. As with any material that is smoked, chronic smoking of marijuana will produce bronchitis; emphysema or lung cancer have not yet been documented. Cardiovascular effects of the drug are harmful to those with preexisting heart disease; fortunately the number of users with such conditions is minimal. Fears that the drug might accumulate in the body to the point of toxicity have been groundless. The potential deleterious effects of marijuana use on driving ability seem to be self- evident; proof of such impairment has been more difficult. The drug is probably harmful when taken during pregnancy, but the risk is uncertain. One would be prudent to avoid marijuana during pregnancy, just as one would do with most other drugs not essential to life or well-being. No clinical consequences have been noted from the effects of the drug on immune response, chromosomes, or cell metabolites. Contamination of marijuana by spraying with defoliants has created the clearest danger to health; such attempts to control production should be abandoned. Therapeutic uses for marijuana, THC, or cannabinoid homologs are being actively explored. Only the synthetic homolog, nabilone, has been approved for use to control nausea and vomiting associated with cancer chemotherapy.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				G. Cacciola, T. Chioccarelli, K. Mackie, R. Meccariello, C. Ledent, S. Fasano, R. Pierantoni, and G. Cobellis Expression of Type-1 Cannabinoid Receptor During Rat Postnatal Testicular Development: Possible Involvement in Adult Leydig Cell Differentiation Biol Reprod, October 1, 2008; 79(4): 758 - 765. [Abstract] [Full Text] [PDF]

				P. Pacher, S. Batkai, and G. Kunos The Endocannabinoid System as an Emerging Target of Pharmacotherapy Pharmacol. Rev., September 1, 2006; 58(3): 389 - 462. [Abstract] [Full Text] [PDF]

				L. J. Sim-Selley, N. S. Schechter, W. K. Rorrer, G. D. Dalton, J. Hernandez, B. R. Martin, and D. E. Selley Prolonged Recovery Rate of CB1 Receptor Adaptation after Cessation of Long-Term Cannabinoid Administration Mol. Pharmacol., September 1, 2006; 70(3): 986 - 996. [Abstract] [Full Text] [PDF]

				K. Murphy, V. Dixon, K. LaGrave, J. Kaufman, R. Risinger, A. Bloom, and H. Garavan A Validation of Event-Related fMRI Comparisons Between Users of Cocaine, Nicotine, or Cannabis and Control Subjects Am J Psychiatry, July 1, 2006; 163(7): 1245 - 1251. [Abstract] [Full Text] [PDF]

				I Mateo, A Pinedo, M Gomez-Beldarrain, J M Basterretxea, and J C Garcia-Monco Recurrent stroke associated with cannabis use J. Neurol. Neurosurg. Psychiatry, March 1, 2005; 76(3): 435 - 437. [Abstract] [Full Text] [PDF]

				C. L. M. Caton, R. E. Drake, D. S. Hasin, B. Dominguez, P. E. Shrout, S. Samet, and W. B. Schanzer Differences Between Early-Phase Primary Psychotic Disorders With Concurrent Substance Use and Substance-Induced Psychoses Arch Gen Psychiatry, February 1, 2005; 62(2): 137 - 145. [Abstract] [Full Text] [PDF]

				M. C. Jockers-ScheruBl, U. Matthies, H. Danker-Hopfe, U. E. Lang, R. Mahlberg, and R. Hellweg Chronic Cannabis Abuse Raises Nerve Growth Factor Serum Concentrations in Drug-Naive Schizophrenic Patients J Psychopharmacol, December 1, 2003; 17(4): 439 - 445. [Abstract] [PDF]

				T. W. Klein, C. Newton, K. Larsen, L. Lu, I. Perkins, L. Nong, and H. Friedman The cannabinoid system and immune modulation J. Leukoc. Biol., October 1, 2003; 74(4): 486 - 496. [Abstract] [Full Text] [PDF]

				S. Hilairet, M. Bouaboula, D. Carriere, G. Le Fur, and P. Casellas Hypersensitization of the Orexin 1 Receptor by the CB1 Receptor: EVIDENCE FOR CROSS-TALK BLOCKED BY THE SPECIFIC CB1 ANTAGONIST, SR141716 J. Biol. Chem., June 20, 2003; 278(26): 23731 - 23737. [Abstract] [Full Text] [PDF]

				L. Iversen Cannabis and the brain Brain, June 1, 2003; 126(6): 1252 - 1270. [Abstract] [Full Text] [PDF]

				G. T. Carter and B. S. Rosen Marijuana in the management of amyotrophic lateral sclerosis American Journal of Hospice and Palliative Medicine, July 1, 2001; 18(4): 264 - 270. [Abstract] [PDF]

				M. A. Mittleman, R. A. Lewis, M. Maclure, J. B. Sherwood, and J. E. Muller Triggering Myocardial Infarction by Marijuana Circulation, June 12, 2001; 103(23): 2805 - 2809. [Abstract] [Full Text] [PDF]

				G. Gerdeman and D. M. Lovinger CB1 Cannabinoid Receptor Inhibits Synaptic Release of Glutamate in Rat Dorsolateral Striatum J Neurophysiol, January 1, 2001; 85(1): 468 - 471. [Abstract] [Full Text] [PDF]

				J. T. KITTLER, E. V. GRIGORENKO, C. CLAYTON, S.-Y. ZHUANG, S. C. BUNDEY, M. M. TROWER, D. WALLACE, R. HAMPSON, and S. DEADWYLER Large-scale analysis of gene expression changes during acute and chronic exposure to {Delta}9-THC in rats Physiol Genomics, September 8, 2000; 3(3): 175 - 185. [Abstract] [Full Text] [PDF]

				G. Griffin, Q. Tao, and M. E. Abood Cloning and Pharmacological Characterization of the Rat CB2 Cannabinoid Receptor J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 886 - 894. [Abstract] [Full Text]

				Z.-H. Song and C.-A. Slowey Involvement of Cannabinoid Receptors in the Intraocular Pressure-Lowering Effects of WIN55212-2 J. Pharmacol. Exp. Ther., January 1, 2000; 292(1): 136 - 139. [Abstract] [Full Text]

				M. Shen and S. A. Thayer Delta 9-Tetrahydrocannabinol Acts as a Partial Agonist to Modulate Glutamatergic Synaptic Transmission between Rat Hippocampal Neurons in Culture Mol. Pharmacol., January 1, 1999; 55(1): 8 - 13. [Abstract] [Full Text]

				D. W. Bonhaus, L. K. Chang, J. Kwan, and G. R. Martin Dual Activation and Inhibition of Adenylyl Cyclase by Cannabinoid Receptor Agonists: Evidence for Agonist-Specific Trafficking of Intracellular Responses J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 884 - 888. [Abstract] [Full Text]

				G. C.-K. Chan, T. R. Hinds, S. Impey, and D. R. Storm Hippocampal Neurotoxicity of Delta 9-Tetrahydrocannabinol J. Neurosci., July 15, 1998; 18(14): 5322 - 5332. [Abstract] [Full Text] [PDF]

				U. D. McCann, K. A. Lowe, and G. A. Ricaurte REVIEW {blacksquare} : Long-lasting Effects of Recreational Drugs of Abuse on the Central Nervous System Neuroscientist, November 1, 1997; 3(6): 399 - 411. [Abstract] [PDF]

				C. S. Breivogel, L. J. Sim, and S. R. Childers Regional Differences in Cannabinoid Receptor/G-protein Coupling in Rat Brain J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1632 - 1642. [Abstract] [Full Text]

				W. Twitchell, S. Brown, and K. Mackie Cannabinoids Inhibit N- and P/Q-Type Calcium Channels in Cultured Rat Hippocampal Neurons J Neurophysiol, July 1, 1997; 78(1): 43 - 50. [Abstract] [Full Text] [PDF]

				F. Rodríguez de Fonseca, M. R. A. Carrera, M. Navarro, G. F. Koob, and F. Weiss Activation of Corticotropin-Releasing Factor in the Limbic System During Cannabinoid Withdrawal Science, June 27, 1997; 276(5321): 2050 - 2054. [Abstract] [Full Text]

				H. Cadas, E. di Tomaso, and D. Piomelli Occurrence and Biosynthesis of Endogenous Cannabinoid Precursor, N-Arachidonoyl Phosphatidylethanolamine, in Rat Brain J. Neurosci., February 15, 1997; 17(4): 1226 - 1242. [Abstract] [Full Text] [PDF]

				K. Kempe, F.-F. Hsu, A. Bohrer, and J. Turk Isotope Dilution Mass Spectrometric Measurements Indicate That Arachidonylethanolamide, the Proposed Endogenous Ligand of the Cannabinoid Receptor, Accumulates in Rat Brain Tissue Post Mortem but Is Contained at Low Levels in or Is Absent from Fresh Tissue J. Biol. Chem., July 19, 1996; 271(29): 17287 - 17295. [Abstract] [Full Text] [PDF]

				M. Bouaboula, B. Bourrié, M. Rinaldi-Carmona, D. Shire, Gér. L. Fur, and P. Casellas Stimulation of Cannabinoid Receptor CB1 Induces krox-24 Expression in Human Astrocytoma Cells J. Biol. Chem., June 9, 1995; 270(23): 13973 - 13980. [Abstract] [Full Text] [PDF]